Tom 16, Nr 5 (2022)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2022-10-31
Wyświetlenia strony 523
Wyświetlenia/pobrania artykułu 20
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Aktualne miejsce inhibitorów DPP-4 w leczeniu cukrzycy typu 2

Dorota Zozulińska-Ziółkiewicz, Irina Kowalska, Maciej Małecki, Grzegorz Dzida, Janusz Gumprecht, Jarosław Woroń, Filip M. Szymański
Forum Medycyny Rodzinnej 2022;16(5):171-181.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. International Diabetes Federation IDF Diabetes Atlas, 10th Edn. https://www.diabetesatlas.org.
  2. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002; 287(3): 360–372.
  3. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012; 51(8): 501–514.
  4. Scott LJ. Sitagliptin: A Review in Type 2 Diabetes. Drugs. 2017; 77(2): 209–224.
  5. Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373(3): 232–242.
  6. Rosenstock J, Kahn SE, Johansen OE, et al. CAROLINA Investigators. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019; 322(12): 1155–1166.
  7. Scirica BM, Braunwald E, Raz I, et al. SAVOR-TIMI 53 Steering Committee and Investigators*. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014; 130(18): 1579–1588.
  8. Thein D, Christiansen MN, Mogensen UM, et al. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovasc Diabetol. 2020; 19(1): 107.
  9. Kim YG, Yoon D, Park S, et al. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study. Circ Heart Fail. 2017; 10(9).
  10. Ou SM, Shih CJ, Chao PW, et al. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med. 2015; 163(9): 663–672.
  11. Kaneko M, Narukawa M. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016; 116: 171–182.
  12. Wang J, Wu HY, Chien KL. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes. Diabetes Metab. 2022; 48(3): 101299.
  13. Araszkiewicz A, Bandurska-Stankiewicz E, Budzyński A, et al. 2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Curr Top Diabetes. 2022; 2: 1–134.
  14. Professional Practice Committee: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022, 45, S3–S3, doi:10.2337/dc22-Sppc.
  15. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12): 2669–2701.
  16. Seidu S, Cos X, Brunton S, et al. A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. Prim Care Diabetes. 2021; 15(1): 31–51.
  17. Seidu S, Cos X, Brunton S, et al. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Prim Care Diabetes. 2022; 16(2): 223–244.
  18. Consoli A, Czupryniak L, Duarte R, et al. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. Diabetes Obes Metab. 2020; 22(10): 1705–1713.
  19. Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2015; 17(3): 268–275.
  20. Phung OJ, Sobieraj DM, Engel SS, et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014; 16(5): 410–417.
  21. Aroda V, González-Galvez G, Grøn R, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2019; 7(8): 596–605.
  22. Matthews D, Paldánius P, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. The Lancet. 2019; 394(10208): 1519–1529.
  23. Kostka-Trąbka E, Woroń J. Interakcje leków w praktyce klinicznej. Wydawnictwo Lekarskie PZWL, Warszawa .